{"id":90100,"date":"2013-02-11T10:46:54","date_gmt":"2013-02-11T15:46:54","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/leading-biotechnology-company-renews-multi-million-dollar-enterprise-agreement-for-omnicomm-systems-trialmaster-edc.php"},"modified":"2024-08-17T15:59:50","modified_gmt":"2024-08-17T19:59:50","slug":"leading-biotechnology-company-renews-multi-million-dollar-enterprise-agreement-for-omnicomm-systems-trialmaster-edc","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/leading-biotechnology-company-renews-multi-million-dollar-enterprise-agreement-for-omnicomm-systems-trialmaster-edc.php","title":{"rendered":"Leading Biotechnology Company Renews Multi-Million Dollar Enterprise Agreement for OmniComm Systems&#39; TrialMaster EDC &#8230;"},"content":{"rendered":"<p><p>    FORT LAUDERDALE, Fla., Feb. 5, 2013 (GLOBE NEWSWIRE) --    OmniComm Systems, Inc. (OMCM),    one of the fastest growing companies in the Electronic Data    Capture (EDC) marketplace, today announced the renewal of an    Enterprise Agreement to deploy TrialMaster(R), their Electronic    Data Capture (EDC) suite, with one of the largest biotechnology    companies in the U.S. This two year agreement is expected to    generate over $2M in revenue during the support of multiple    clinical trial programs.  <\/p>\n<p>    \"We are honored that this leading biotech client has again    chosen to partner with OmniComm for their clinical research    needs,\" commented Stephen Johnson, OmniComm's President &    COO. \"This is a strong testament to the quality of the products    and services that OmniComm delivers, and we look forward to    continuing this fruitful partnership.\"  <\/p>\n<p>    This contract renewal is the latest in a string of new and    recurring business with biotech clients. OmniComm attributes    its success to many new innovative functions and features    across its multiple product lines, and to its strong customer    service and support programs.  <\/p>\n<p>    \"Biotechnology companies are at the forefront of medical    research, and often need very sophisticated features to    implement their study designs,\" commented Keith Howells,    OmniComm's Senior Vice President of Development. \"TrialMaster    includes features such as guided data entry, risk-based    monitoring and out-of-the-box generation of submission-ready    datasets, which are very attractive to this industry. We are    proud of this latest endorsement of our innovation strategy.\"  <\/p>\n<p>    About OmniComm  <\/p>\n<p>    OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven    Internet solutions to pharmaceutical, biotechnology, and    medical device organizations that conduct life changing    clinical trial research. OmniComm's growing base of satisfied    customers is a direct result of the company's commitment to    deliver products and services that ensure ease of use, faster    study build, ease of integration and better performance.    OmniComm Systems, Inc. has U.S. headquarters in Fort    Lauderdale, FL and European headquarters in Bonn, Germany, with    satellite offices in New Jersey and the United Kingdom, as well    as sales offices throughout the U.S. and Europe.  <\/p>\n<p>    The OmniComm Systems Inc. logo is available at     <a href=\"http:\/\/www.globenewswire.com\/newsroom\/prs\/?pkgid=13414\" rel=\"nofollow\">http:\/\/www.globenewswire.com\/newsroom\/prs\/?pkgid=13414<\/a>  <\/p>\n<p>    Safe Harbor Disclaimer  <\/p>\n<p>    Statements made by OmniComm included in this release may    constitute forward-looking statements within the meaning of the    Private Securities Litigation Reform Act of 1995. Such    statements involve a number of risks and uncertainties such as    the Company's ability to obtain new contracts and accurately    estimate net revenues due to uncertain regulatory guidance,    variability in size, scope and duration of projects, and    internal issues at the sponsoring client, integration of    acquisitions, competitive factors, technological development,    and market demand. As a result, actual results may differ    materially from any financial outlooks stated herein. Further    information on potential factors that could affect the    Company's financial results can be found in the Company's    Reports on Form 10-K and 10-Q filed with the Securities and    Exchange Commission. The Company undertakes no obligation to    publicly update any forward-looking statement, whether as a    result of new information, future events, or otherwise.  <\/p>\n<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read more from the original source:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/leading-biotechnology-company-renews-multi-131000919.html;_ylt=A2KLOzFEEhlR2DoAcTb_wgt.\" title=\"Leading Biotechnology Company Renews Multi-Million Dollar Enterprise Agreement for OmniComm Systems&#39; TrialMaster EDC ...\" rel=\"noopener\">Leading Biotechnology Company Renews Multi-Million Dollar Enterprise Agreement for OmniComm Systems&#39; TrialMaster EDC ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> FORT LAUDERDALE, Fla., Feb. 5, 2013 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced the renewal of an Enterprise Agreement to deploy TrialMaster(R), their Electronic Data Capture (EDC) suite, with one of the largest biotechnology companies in the U.S <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/leading-biotechnology-company-renews-multi-million-dollar-enterprise-agreement-for-omnicomm-systems-trialmaster-edc.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-90100","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/90100"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=90100"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/90100\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=90100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=90100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=90100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}